April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Proliferative Radiation Retinopathy Following Plaque Brachytherapy for Uveal Melanoma
Author Affiliations & Notes
  • C. G. Bianciotto
    Ocular Oncology, Wills Eye Institute, Philadelphia, Pennsylvania
  • C. L. Shields
    Ocular Oncology, Wills Eye Institute, Philadelphia, Pennsylvania
  • C. Pirondini
    Ocular Oncology, Wills Eye Institute, Philadelphia, Pennsylvania
  • A. Mashayekhi
    Ocular Oncology, Wills Eye Institute, Philadelphia, Pennsylvania
  • M. Furuta
    Ocular Oncology, Wills Eye Institute, Philadelphia, Pennsylvania
  • J. A. Shields
    Ocular Oncology, Wills Eye Institute, Philadelphia, Pennsylvania
  • Footnotes
    Commercial Relationships  C.G. Bianciotto, None; C.L. Shields, None; C. Pirondini, None; A. Mashayekhi, None; M. Furuta, None; J.A. Shields, None.
  • Footnotes
    Support  Support provided by the Retina Research Foundation of the Retina Society in Cape Town, South Africa (CLS); the Paul Kayser International Award of Merit in Retina Research, Houston TX (JAS); a donation
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 5756. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C. G. Bianciotto, C. L. Shields, C. Pirondini, A. Mashayekhi, M. Furuta, J. A. Shields; Proliferative Radiation Retinopathy Following Plaque Brachytherapy for Uveal Melanoma. Invest. Ophthalmol. Vis. Sci. 2009;50(13):5756.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To determine risk factors, incidence, management and outcome of treatment of proliferative radiation retinopathy (PRR) after plaque radiotherapy for uveal melanoma.

Methods: : Retrospective review of medical records.Main outcome measure: The occurrence of PRR after plaque radiotherapy for uveal melanoma.

Results: : Of 3841 eyes treated with plaque radiotherapy for uveal melanoma, PRR developed in 0.3% of patients at 1 year, 1.7% at 2 years, 5.8% at 5 years and 7% at 10 and 15 years using Kaplan-Meier analysis. The mean time to onset of RPR was 32 months. On univariate analysis factors predictive of PRR (p<0.05) included younger age, diabetes, shorter tumor distance to the optic disc and the foveola, Bruchs’ membrane rupture, mushroom tumor shape, choroidal location of the tumor, higher radiation dose to the optic nerve and to the foveola, and notched plaque. In the multivariate model, younger age and diabetes were related to the occurrence of PRR. The most common forms of management included panretinal photocoagulation (70%), vitrectomy (21%), observation (17%) and enucleation (11%).

Conclusions: : PRR develops in 7% of eyes by 10 years following plaque radiotherapy for uveal melanoma. The main factors for development of PRR on the multivariate analysis were diabetes and younger age of the patients at presentation.

Keywords: melanoma • radiation therapy • neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×